Clinical Trials Logo
  1. Home
  2. Oropharynx Cancer
  3. NCT05800574

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Oropharynx Cancer Clinical Trial

Official title:
A Phase II Investigation of Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer Patients Managed With Primary (Chemo) Radiation

Clinical Trial Summary

This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.

Clinical Trial Description

This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck. Patients positive for p16 status will be approached for consent during the pre-treatment intake process. Contralateral neck progression will be measured by PET (positron emission tomography)/CT scans. Xerostomia will be measured by the EORTC QLQ (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire) H&N35 at 6, 12, and 24 months. Patients will remain on study treatment for 6-7 weeks or until unacceptable toxicity or withdrawal of consent. Disease free survival (DFS) and overall survival (OS) will be assessed until 24 months after completion of study treatment ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05800574
Study type Interventional
Source Fox Chase Cancer Center
Contact Ryan Romasko
Phone 2678388380
Email ryan.romasko@fccc.edu
Status Recruiting
Phase Phase 2
Start date March 14, 2023
Completion date September 23, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Completed NCT00158678 - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Phase 3
Recruiting NCT04567082 - Proteome- and Methylation Profiles in Oropharyngeal Cancer
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Completed NCT03435471 - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer N/A
Completed NCT05055206 - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers N/A
Recruiting NCT04359199 - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Active, not recruiting NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Phase 3
Active, not recruiting NCT00232960 - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC N/A
Completed NCT05698667 - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer N/A
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Not yet recruiting NCT06276946 - Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia N/A
Completed NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Phase 2
Terminated NCT01066741 - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Phase 3
Completed NCT03418792 - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx N/A